DAJH-1050766

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameDAJH-1050766
Drug Alias NameDAJH-1050766DAJH1050766DA-0157
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsEGFR C797S inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1Anaplastic lymphoma kinaseEGFR C797S
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu Diao Jiuhong Pharmaceutical Factory
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Diao Jiuhong Pharmaceutical Factory
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A